ABT

In the past six months (April-October 2026), Abbott's stock (ABT) experienced several notable events. On March 24, 2026, S&P Global Ratings downgraded Abbott's issuer credit rating to 'A+' from 'AA-' due to increased leverage from its $23 billion acquisition of Exact Sciences. The stock price decreased by 25.84% over the last 12 months and 8.49% in the past month as of October 6, 2026, reaching a 9-week low of $100.32 on September 25, 2026, and an earlier 4-week low of $106.72 on September 8, 2026. However, on August 11, 2026, shares increased to a 21-week high of $110.08, and on October 5, 2026, the stock rose by 3.08% following FDA approval for new capabilities in its CardioMEMS heart failure system. The company is expected to report Q3 2026 earnings on October 21, 2026, with an anticipated 10% rise in EPS to $1.43 year-over-year, and is expected to pay a quarterly dividend of $0.63 per share with an ex-dividend date of October 15, 2026.